How Do “Altruistic” Reg. Pathways Expedite/Optimize the Avail. of New Meds

Altruistic regulatory pathways such as M4All, MAGHP, and the WHO Collaborative Registration Procedure (CRP) have reshaped global health policy by enabling faster, more equitable access to medicines. Their value lies not only in technical efficiency but in the policy impact of fostering reliance, reducing duplication, and strengthening trust among regulators. These pathways demonstrate how collaborative frameworks can shift policy norms toward harmonization, transparency, and shared responsibility. By prioritizing public health outcomes over commercial interests, they influence national policies, encourage capacity building, and set precedents for sustainable, globally aligned regulatory practices that advance equity and access worldwide. Join us as we explore updates on the use and value of these and other important registration pathways.

The agenda is as follows:

Topic 1: How do these specialized pathways contribute to regulatory strengthening and medicine availability: an Introduction- Dr. Murray (Mac) Lumpkin, Deputy Director Integrated Development (Lead for Global Regulatory Systems Initiatives) at The Gates Foundation

Topic 2: WHO Specialized Pathways: and Update in the CRP - Dr. Mariana Roldao Santos, Technical Officer, Facilitated Product Introduction, Regulation, World Health Organization

Topic 3: The Benefits of Participating in the Use of Altruistic Pathways - Dr. Odbiambo David, Executive Director, African Pharmaceutical Network

The webinar is schedule for 9:00am to 10:15am Eastern Time on Wednesday, December 16th, 2025.

Want more information? Contact us at frpath@erudee.org

Follow the FRPath Project on LinkedIn HERE